In cancer cells, EphA2 exhibits a dual role: its ligand-dependent function inhibits cancer cell invasion and migration upon ligand binding, whereas its ligand-independent kinase activity involves overexpressed EphA2 altering downstream signaling pathways through dimerization with E-cadherin, EGFR, HER2, and integrins. Here, CDH1 is linked to cancer.